Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib
- 1 February 2013
- journal article
- research article
- Published by Elsevier BV in European Journal of Surgical Oncology
- Vol. 39 (2), 150-155
- https://doi.org/10.1016/j.ejso.2012.09.004
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trialBMC Cancer, 2011
- Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST)European Journal of Surgical Oncology, 2009
- Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trialThe Lancet, 2009
- Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665Journal of Surgical Oncology, 2008
- We Should Desist Using RECIST, at Least in GISTJournal of Clinical Oncology, 2007
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004
- Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumoursBritish Journal of Surgery, 2003
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsThe New England Journal of Medicine, 2002
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal TumorsScience, 1998
- Prognostic Factors Influencing Survival in Gastrointestinal Leiomyosarcomas Implications for Surgical Management and StagingAnnals of Surgery, 1992